Overview A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors Status: Recruiting Trial end date: 2024-10-01 Target enrollment: Participant gender: Summary This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors. Phase: Phase 1/Phase 2 Details Lead Sponsor: NextCure, Inc.